Nimbus Therapeutics is a biotechnology company that designs and develops small molecule therapeutics using cutting-edge tools and technologies to solve complex drug discovery challenges.

Nimbus Therapeutics

At Nimbus, we design breakthrough medicines. Utilizing our powerful structure-based drug discovery engine, we create potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. With a decade-plus track record of success, we’ve built a world-class team in both computationally driven drug discovery and early clinical development while continuing to move the needle for patients. 

Pfizer Venture Investments

RA Capital Management

Lightstone Ventures

SR One

SV Health Investors

Gates Frontier fund

Google Ventures

Atlas Venture

Bain Capital Life Sciences

BVF Partners

Lilly Ventures

Schrödinger

Bill Gates

Access Biotechnology

Biotechnology Value Fund

Surveyor Capital

Commodore Capital

Logos Capital

We were inspired by the energy in the room at the Life Science Cares Boston IMPACT breakfast this week! Proud to be a part of a community focused on giving back to our city in ways that can make a meaningful difference.

This week #Nimbi had the opportunity to join CEO Jeb Keiper and Katharine Knobil, M.D., the newest member of our Board of Directors, in a fireside chat. Kate shared many valuable insights from more than two decades of experience leading research and development at both small biotech and large pharma companies. It was a wonderful introduction, and we can’t wait to see what we will accomplish together!

Today Luke Timmerman joined #Nimbi for a special "Lunch & Learn" session. 

Most know Luke as a distinguished journalist who has been covering the #biotech sector since 2001. He is also a seasoned explorer who has led multiple expeditions around the globe, raising over $9M for causes ranging from poverty to cancer research. Our Chief Business Officer, Abbas Kazimi, joined Luke on Mount Kilimanjaro this year. And Chief Executive Officer Jeb Keiper hiked the Presidential Traverse with Luke in 2021. 

Luke shared what motivates him to be a catalyst for social impact and how he hopes to inspire others to do the same. 

You can listen to Luke’s conversation with Jeb on “The Long Run” podcast via Timmerman Report here: https://lnkd.in/ekuwTazR

We were thrilled to welcome a panel of powerhouse women in the life sciences yesterday for an inspiring conversation that was the highlight of our month-long celebration of #InternationalWomensDay. 
  
Our esteemed panelists — Rosana Kapeller, Sarah A. Solomon, Anne McGeorge and Helen Ho — shared their journeys to where they are today, the obstacles that they've navigated in their careers, and the lessons that they hope will empower the next wave of women leaders in biotech.  
   
 #WomensHistoryMonth #womenshistory #womeninscience 

Metric
Company Name	Nimbus Therapeutics
Symbol
MSH ID	COM:NIMBUSTX
Market	PRIVATE
Sector	Energy
Industry	Biotechnology
Country	US
Stage
Employee Count	100
Website	nimbustx.com
LinkedIn	nimbus-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	10.97
28-Day Growth Score	15.73
90-Day Growth Score	9.06
365-Day Growth Score	30.48

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:NIMBUSTX

Nimbus Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue